MSD and Isomorphic join forces to develop oncology drugs
MSD (Merck & Co) has forged a partnership with British artificial intelligence (AI)-powered biotech Isomorphic Labs, which will see the…
MSD (Merck & Co) has forged a partnership with British artificial intelligence (AI)-powered biotech Isomorphic Labs, which will see the…
Faced with a steep cliff of patent expirations for some of its key commercial assets, Novartis has shone a light on its pipeline as it seeks to ease investor fears…
Sanofi is reportedly mulling a takeover bid for respiratory disease-focused biotech Insmed as the company approaches an M&A-heavy dealmaking strategy under its new CEO Belén Garijo. As per Bloomberg, which…
Recursion Pharmaceuticals has secured alignment with the FDA on a novel endpoint for its planned Phase III trial of REC-4881, an investigational treatment for familial adenomatous polyposis (FAP). Speaking at…
While M&A appetite has been strong in 2026, deals are increasingly thwarted by valuation gaps, geopolitical uncertainty and greater selectivity among buyers. Reflecting on the year, industry experts at the…
London-based Ellipses Pharma said it might conduct an initial public offering (IPO) on home soil, an announcement that could mark the end for one of the longest ever dry spells…
Lineage Cell Therapeutics is acquiring fellow Californian biotech company NeuroAirmid Therapeutics – officially adding a novel Huntington’s disease therapy to its pipeline. Through this takeover, which saw Lineage outlay $4.7m…